Transmedics Group Inc. operates under a business model focused on the development and commercialization of organ transplant solutions. The company specializes in designing and producing innovative medical devices and systems that preserve, monitor, and assess organs intended for transplantation. By harnessing cutting-edge technology, Transmedics' business model aims to improve both donor organ quality and transplantation outcomes. Through its offerings, the company seeks to address critical challenges faced by organ transplant patients and healthcare professionals worldwide. Transmedics Group Inc. continues to drive innovation in the organ transplant field through its comprehensive product portfolio and commitment to advancing patient care.

Transmedics Group Inc is primarily active in the biomedical industry.

The main competitors of Transmedics Group Inc in the market include Medtronic, Inc., XVIVO Perfusion AB, and OrganAssist BV.

Transmedics Group Inc is a leading medical technology company specializing in organ transplant solutions. Founded in 1998, the company has been dedicated to improving outcomes for patients awaiting organ transplants. With its groundbreaking Organ Care System (OCS), Transmedics revolutionized the field by allowing organs to be preserved and assessed outside the traditional cold storage method. This breakthrough technology ensures organs remain at the optimal physiological condition, significantly increasing the chances of successful transplants. Transmedics is committed to continuing innovation and expanding its global presence to address the critical need for organ transplantation worldwide.

Transmedics Group Inc has achieved several significant milestones. Notably, the company successfully developed the Organ Care System (OCS), a breakthrough technology that allows for the preservation and transportation of donor organs. The OCS has revolutionized the field of transplant medicine by extending the time organs can remain outside the body, increasing the chances of successful transplantation. Additionally, Transmedics Group Inc received regulatory approvals for the OCS in major markets, including the United States and Europe. These achievements have solidified the company's position as a leader in the advancement of organ transplantation, benefiting countless patients worldwide.

Transmedics Group Inc is primarily present in the United States.

Transmedics Group Inc represents a commitment to innovation and improving organ transplant outcomes. The company's corporate philosophy centers around its Organ Care System (OCS) technology, which enables the preservation and assessment of donated organs for transplantation. Transmedics Group Inc values the advancements made in organ transplantation, aiming to improve patient outcomes and increase the number of viable organs available for transplant. By leveraging their OCS technology, the company strives to address the critical organ shortage challenge and revolutionize the transplantation field. Through their dedication to innovation and patient-centric approach, Transmedics Group Inc constantly aims to make a positive impact in the field of organ transplantation.

Analysts currently set an average price target of 148,92 USD for the Transmedics Group stock (median: 151,98 USD), implying +95,6 % versus the latest price. The consensus is based on 20 analyst ratings.

Transmedics Group Analyytikkojen kursstavoitteet 2026

20 analysts currently rate the Transmedics Group stock: 16 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Transmedics Group to generate revenue of 732,29 M USD and earnings per share of 1,49 USD.

Transmedics Group Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Transmedics Group share trades at 63,47 EUR (73,06 USD).

The Transmedics Group share (TMDX) is listed on 3 stock exchanges, including: NASDAQ (TMDX), Frankfurt (8T8.F), München (8T8.MU).

The Transmedics Group Inc is a leading provider of advanced organ care systems for transplantation medicine. The company offers an innovative platform that allows organs to be obtained, protected, transported, and transplanted outside of the body. The company is divided into three main business areas: 1. Organ Care System The Organ Care System (OCS) is a groundbreaking technology that revolutionizes organ care and transplantation. It is a portable, modular system that enables doctors to obtain and protect donor organs outside of the body. The OCS was developed to increase the survival rate of donor organs and reduce the number of transplant rejections. 2. Organ Transport & Storage Solutions The company offers a variety of organ transport and storage solutions that meet the needs of customers. The transport and storage systems are FDA-certified and provide optimal conditions for successful transplantation. 3. Organ Care Services Organ Care Services (OCS) are a key part of Transmedics' business operations. The company offers a wide range of services tailored to the specific needs of customers. These include organ storage, preparation for transplantation, and support during surgeries. Transmedics is an innovative company protected by a number of patents and intellectual property. The company heavily invests in research and development and stays at the forefront of technology to maintain its position as a leader in organ transplantation. In summary, Transmedics Group Inc is a pioneer in the field of organ transplantation. With its offering of advanced organ care systems, the company has revolutionized transplantation medicine and established itself as a leading provider. Transmedics is well-positioned to continue growing and meeting the needs of its customers while helping to save lives.

odotettu liikevaihto Transmedics Group on 732,29 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Transmedics Group on 60,98 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Transmedics Group:n hinta-voitto-suhde (P/E) on tällä hetkellä 49,04. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Transmedics Group-osakkeen arvostusta.

Transmedics Group:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,08. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Transmedics Group-osakkeen arvostuskennuslukuna.

Transmedics Group:n Eulpool-laatuscore on 6/10.

Transmedics Group:n ISIN on US89377M1099. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Transmedics Group:n WKN on A2PH5P. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Transmedics Group:n ticker on TMDX. Tämä pörssinoteeraus käytetään Transmedics Group-osakkeiden kauppaan pörssissä.

Transmedics Group maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Transmedics Group kuuluu sektoriin 'Terveydenhuolto'.

Transmedics Group:n osingot jaetaan valuutassa USD.